GlaxoSmithKline (LON:GSK) Given “Sell” Rating at Morgan Stanley
Morgan Stanley reissued their sell rating on shares of GlaxoSmithKline (LON:GSK) in a research report released on Tuesday, January 7th, Borsen Zeitung reports. The brokerage currently has a GBX 1,740 ($22.89) price target on the stock.
A number of other equities research analysts have also weighed in on GSK. Bank of America set a GBX 1,900 ($24.99) target price on GlaxoSmithKline and gave the company a neutral rating in a research report on Friday, September 13th. Bryan, Garnier & Co raised their price target on GlaxoSmithKline from GBX 1,660 ($21.84) to GBX 1,747 ($22.98) and gave the company a neutral rating in a research note on Thursday, December 19th. Goldman Sachs Group set a GBX 1,900 ($24.99) price objective on GlaxoSmithKline and gave the company a buy rating in a report on Wednesday, October 30th. HSBC set a GBX 2,110 ($27.76) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a research note on Wednesday, December 18th. Finally, UBS Group reissued a buy rating and set a GBX 1,900 ($24.99) target price on shares of GlaxoSmithKline in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the stock. GlaxoSmithKline presently has an average rating of Hold and an average target price of GBX 1,872.47 ($24.63).
Shares of LON:GSK opened at GBX 1,809.20 ($23.80) on Tuesday. GlaxoSmithKline has a one year low of GBX 1,429.80 ($18.81) and a one year high of GBX 1,850.40 ($24.34). The firm has a market cap of $90.27 billion and a PE ratio of 19.82. The firm’s 50 day simple moving average is GBX 1,770.65 and its 200-day simple moving average is GBX 1,700.81. The company has a debt-to-equity ratio of 183.00, a quick ratio of 0.50 and a current ratio of 0.82.
The company also recently declared a dividend, which was paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th were given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.07%. The ex-dividend date of this dividend was Thursday, November 14th. GlaxoSmithKline’s payout ratio is 1.01%.
In other news, insider Vivienne Cox acquired 308 shares of GlaxoSmithKline stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of GBX 1,725 ($22.69) per share, for a total transaction of £5,313 ($6,988.95). In the last ninety days, insiders bought 330 shares of company stock worth $569,837.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Recommended Story: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.